Anavex Life Sciences (AVXL) Other Operating Expenses (2020)

Anavex Life Sciences (AVXL) reported Other Operating Expenses of -$62.2 million for Q3 2020.

Anavex Life Sciences (AVXL) Other Operating Expenses (2020) Analysis & Trends

Anavex Life Sciences (AVXL) has 1 years of Other Operating Expenses data on file, last reported at -$62.2 million in Q3 2020.

For the quarter ending Q3 2020, Other Operating Expenses changed N/A year-over-year to -$62.2 million; the trailing twelve-month figure through Jun 2021 stood at -$62.2 million (changed N/A YoY), and the FY2020 full-year result was -$62.2 million, changed N/A from the prior year.
Other Operating Expenses held at -$62.2 million in Q3 2020.
In the past five years, Other Operating Expenses ranged from a high of -$62.2 million in Q3 2020 to a low of -$62.2 million in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Anavex Life Sciences	229.83 Mn	98.08 Mn	-

Download Data

Date	Value
Sep 30, 2020	-62.18 Mn